PrognomIQ key facts
as of Oct 2026- Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases.
- PrognomIQ is valued at approximately $315.6M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $171.8M across 3 recorded rounds; the latest was Early Stage VC ($11.9M) in Jan 2026.
- Notable investors include Emerson Collective, Wing Venture Capital, Catalio Capital Management, T. Rowe Price Group, Fidelity — 12 tracked in total.
- 1 institutional filer reports fund marks on PrognomIQ across 5 filings.
- PrognomIQ has filed 2 Form Ds with the SEC since 2024, most recently Aug 2025 ($10.0M sold to 9 investors).
- Status: Privately Held (backing).
Reported valuation; nothing comparable since.
- ·The complete investor list: 12 names
- ·Watch PrognomIQ: the Monday email on marks, rounds and moves
Institutional fund marks on PrognomIQ
1 filers · latest May 20261 SEC-registered fund reported 5 fair-value marks on PrognomIQ between May 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
PrognomIQ funding rounds
3 roundsWho backs PrognomIQ
12+Membership and data by Private Market View
PrognomIQ valuation
PrognomIQ is valued at approximately $316 million as of Oct 2026. The figure is set by institutional fund marks.
How much has PrognomIQ raised?
PrognomIQ has raised $172 million in total; 3 of its rounds are on record, from 2024 on. The largest on record was a $34.3 million early-stage round in Aug 2024; the most recent was an $11.9 million early-stage round in Jan 2026.
PrognomIQ has filed 2 Form Ds with the SEC since 2024, most recently in Aug 2025 ($10 million sold to 9 investors).
Institutional holders and vehicles
1 SEC-registered fund reported 5 fair-value marks on PrognomIQ between May 2025 and May 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
PrognomIQ investors
12 investors are on record for PrognomIQ, including Emerson Collective, Wing Venture Capital, Catalio Capital Management and T. Rowe Price Group. The early-stage round in Jan 2026 drew 6 investors.
About PrognomIQ
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2020
- Employees
- 49
- Website
- prognomiq.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.